Literature DB >> 20136697

Paxillin expression levels are correlated with clinical stage and metastasis in salivary adenoid cystic carcinoma.

Jinna Shi1, Shan Wang, Eryang Zhao, Lei Shi, Xin Xu, Ming Fang.   

Abstract

AIMS: To investigate the relationship between paxillin expression and clinicopathological features and metastasis in salivary adenoid cystic carcinoma (SACC).
METHODS: A total of 47 SACC were assessed histochemically for paxillin expression. Paxillin immunoreactivity was compared with histological type, clinical stage and distant metastasis.
RESULTS: Paxillin expression was identified in 57.45% of SACC as cytoplasmic staining and the expression was correlated with distant metastasis and clinical stage (P < 0.05), but not with histological type.
CONCLUSIONS: Our observations indicate that paxillin expression is upregulated in SACC. High expression of paxillin was correlated with a more advanced stage and metastasis in SACC, suggesting that paxillin is a disease marker in advanced SACC and SACC with distant metastasis, and, consequently, may have value as a therapeutic target for SACC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20136697     DOI: 10.1111/j.1600-0714.2009.00859.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  13 in total

1.  Roles for crk in cancer metastasis and invasion.

Authors:  Masumi Tsuda; Shinya Tanaka
Journal:  Genes Cancer       Date:  2012-05

2.  Diverse roles for the paxillin family of proteins in cancer.

Authors:  Nicholas O Deakin; Jeanine Pignatelli; Christopher E Turner
Journal:  Genes Cancer       Date:  2012-05

3.  Paxillin controls directional cell motility in response to physical cues.

Authors:  Julia E Sero; Alexandra E German; Akiko Mammoto; Donald E Ingber
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

4.  Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer.

Authors:  Dong-Liang Chen; De-Shen Wang; Wen-Jing Wu; Zhao-Lei Zeng; Hui-Yan Luo; Miao-Zhen Qiu; Chao Ren; Dong-Sheng Zhang; Zhi-Qiang Wang; Feng-Hua Wang; Yu-Hong Li; Tie-Bang Kang; Rui-Hua Xu
Journal:  Carcinogenesis       Date:  2012-12-28       Impact factor: 4.944

5.  Distinct roles for paxillin and Hic-5 in regulating breast cancer cell morphology, invasion, and metastasis.

Authors:  Nicholas O Deakin; Christopher E Turner
Journal:  Mol Biol Cell       Date:  2011-02-01       Impact factor: 4.138

6.  The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.

Authors:  Kyunghee Noh; Duc-Hiep Bach; Hyun-Jin Choi; Mark S Kim; Sherry Y Wu; Sunila Pradeep; Cristina Ivan; Min-Soon Cho; Emine Bayraktar; Cristian Rodriguez-Aguayo; Santosh K Dasari; Elaine Stur; Lingegowda S Mangala; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Oncogene       Date:  2020-11-04       Impact factor: 9.867

7.  Fascin-1, ezrin and paxillin contribute to the malignant progression and are predictors of clinical prognosis in laryngeal squamous cell carcinoma.

Authors:  Wei Gao; Chunming Zhang; Yan Feng; Ganggang Chen; Shuxin Wen; Hui Huangfu; Binquan Wang
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

8.  Expression of Paxillin is Correlated with Clinical Prognosis in Colorectal Cancer Patients.

Authors:  Cheng-jin Zhao; Shuang-kuan Du; Xing-bo Dang; Min Gong
Journal:  Med Sci Monit       Date:  2015-07-10

9.  Paxillin expression is closely linked to the pathogenesis, progression and prognosis of gastric carcinomas.

Authors:  Li-Jun Xiao; En-Hong Zhao; Shuang Zhao; Xin Zheng; Hua-Chuan Zheng; Yasuo Takano; Hong-Ru Song
Journal:  Oncol Lett       Date:  2013-11-19       Impact factor: 2.967

10.  Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer.

Authors:  Dong-liang Chen; Zhi-qiang Wang; Chao Ren; Zhao-lei Zeng; De-shen Wang; Hui-yan Luo; Feng Wang; Miao-zhen Qiu; Long Bai; Dong-sheng Zhang; Feng-hua Wang; Yu-hong Li; Rui-hua Xu
Journal:  J Transl Med       Date:  2013-11-02       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.